Unknown

Dataset Information

0

The role of toxins in Clostridium difficile infection.


ABSTRACT: Clostridium difficile is a bacterial pathogen that is the leading cause of nosocomial antibiotic-associated diarrhea and pseudomembranous colitis worldwide. The incidence, severity, mortality and healthcare costs associated with C. difficile infection (CDI) are rising, making C. difficile a major threat to public health. Traditional treatments for CDI involve use of antibiotics such as metronidazole and vancomycin, but disease recurrence occurs in about 30% of patients, highlighting the need for new therapies. The pathogenesis of C. difficile is primarily mediated by the actions of two large clostridial glucosylating toxins, toxin A (TcdA) and toxin B (TcdB). Some strains produce a third toxin, the binary toxin C. difficile transferase, which can also contribute to C. difficile virulence and disease. These toxins act on the colonic epithelium and immune cells and induce a complex cascade of cellular events that result in fluid secretion, inflammation and tissue damage, which are the hallmark features of the disease. In this review, we summarize our current understanding of the structure and mechanism of action of the C. difficile toxins and their role in disease.

SUBMITTER: Chandrasekaran R 

PROVIDER: S-EPMC5812492 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

The role of toxins in Clostridium difficile infection.

Chandrasekaran Ramyavardhanee R   Lacy D Borden DB  

FEMS microbiology reviews 20171101 6


Clostridium difficile is a bacterial pathogen that is the leading cause of nosocomial antibiotic-associated diarrhea and pseudomembranous colitis worldwide. The incidence, severity, mortality and healthcare costs associated with C. difficile infection (CDI) are rising, making C. difficile a major threat to public health. Traditional treatments for CDI involve use of antibiotics such as metronidazole and vancomycin, but disease recurrence occurs in about 30% of patients, highlighting the need for  ...[more]

Similar Datasets

| S-EPMC3153265 | biostudies-literature
| S-EPMC5453186 | biostudies-literature
| S-EPMC8118380 | biostudies-literature
| S-EPMC5560262 | biostudies-other
2012-01-06 | E-GEOD-29008 | biostudies-arrayexpress
| S-EPMC7042015 | biostudies-literature
| S-EPMC3986317 | biostudies-literature
2012-01-06 | GSE29008 | GEO
| S-EPMC3417631 | biostudies-literature
| S-EPMC6386544 | biostudies-literature